HLAVNÍ TÉMA Revmatoidní artritida jako interní choroba | 365 / Vnitř Lék. 2024;70(6):358-365 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz podstatně ovlivnit i pacientovo globální hodnocení choroby. Při sledování pacientů s RA však nelze zapomínat ani na další závažné choroby (karcinom prsu, prostaty), které se vyskytují v míře srovnatelné s běžnou populací. PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Publikace byla zpracována s využitím uvedené literatury a nebyla publikována ani zaslána k recenznímu řízení do jiného média. Střet zájmů: Žádný. Financování: Podpořeno MZ ČR RVO FNOL-0098892 a IGA_LF_2024_004. Registrace v databázích: N/A. Projednání etickou komisí: N/A. LITERATURA 1. Turesson C, O‘Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62:722. 2. Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol. 2011;8:983. 3. Guellec D, Cozien S, Ruyssen-Witrand A, et al. Prevalence and clinical significance of extra-articular manifestations at diagnosis in the ESPOIR cohort with recent-onset arthritis. Semin Arthritis Rheum. 2020;50:409. 4. Chandrashekara S, Shobha V, Dharmanand BG, et al. Reduced incidence of extra-articular manifestations of RA through effective disease control: Karnataka Rheumatoid Arthritis Comorbidity (KRAC) study. Int J Rheum Dis 2017; 20:1694. 5. Wolfe F, Mitchell DM, Sibley JT, et al. Th e mortality of rheumatoid arthritis. Arthritis Rheum. 1994;4:481-494. 6. Duffield SJ, Miller N, Zhao S, Goodson NJ. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2018;57:1453. 7. Turk MA, Hayworth JL, Nevskaya T, Pope JE. Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. J Rheumatol. 2021;48:25. 8. Silva B, Cardozo J, Marback P, Machado F, Galvão V, Santiago M. Peripheral ulcerative keratitis: a serious complication of rheumatoid arthritis. Rheum Int. 2010;30(9):1267-8. 9. Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol. 2004;33:65. 10. Kimbrough BA, Crowson CS, Davis JM 3rd, et al. Decline in Incidence of Extra-Articular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study. Arthritis Care Res (Hoboken) 2024;76:454. 11. Patatanian E, Thompson DF. A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy. 2002;22:1157. 12. Maldonado I, Eid H, Rodriguez GR, et al. Rheumatoid nodulosis: is it a different subset of rheumatoid arthritis? J Clin Rheumatol. 2003;9:296. 13. Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum. 2006;35:368. 14. Lawry GV, Finerman ML, Hanafee WN, et al. Laryngeal involvement in rheumatoid arthritis. A clinical, laryngoscopic, and computerized tomographic study. Arthritis Rheum. 1984;27:873. 15. Greco A, Fusconi M, Macri GF, et al. Cricoarytenoid joint involvement in rheumatoid arthritis: radiologic evaluation. Am J Otolaryngol. 2012;33:753. 16. Devouassoux G, Cottin V, Lioté H, et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J. 2009;33:1053. 17. Remy-Jardin M, Remy J, Cortet B, et al. Lung changes in rheumatoid arthritis: CT findings. Radiology. 1994;193:375. 18. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62:1583-1591. 19. Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76:1700-1706. 20. Hyldgaard C, Ellingsen T, Hilberg O, et al. Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality. Respiration. 2019;98:455-460. 21. Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021 Jun 23;30(160):210011. 22. Mertz P, Wollenschlaeger C, Chasset F, et al. Rheumatoid vasculitis in 2023: Changes and challenges since the biologics era. Autoimmun Rev. 2023;22:103391. 23. Karie S, Gandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 2008;47:350. 24. Hickson LJ, Crowson CS, Gabriel SE, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63:206. 25. Sim MK, Kim DY, Yoon J, Park DH, Kim YG. Assessment of peripheral neuropathy in patients with rheumatoid arthritis who complain of neurologic symptoms. Ann Rehabil Med. 2014 Apr;38(2):249-55. 26. Owlia MB, Newman K, Akhtari M. Felty’s Syndrome, Insights and Updates. Open Rheumatol J. 2014 Dec 31;8:129-36. 27. Gridley G, Klippel JH, Hoover RN, Fraumeni JF Jr. Incidence of cancer among men with the Felty syndrome. Ann Intern Med. 1994;120:35. 28. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;4:481-494. 29. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;1:62-68. 30. Oreská S, Tomčík M. KV riziko u revmatických onemocnění. Cas Lek Cesk. 2016;155(6):324-332. 31. Luque Ramos A, Redeker I, Hoffmann F, Callhoff J, Zink A, Albrecht K. Comorbidities in Patients with Rheumatoid Arthritis and Their Association with Patient-reported Outcomes: Results of Claims Data Linked to Questionnaire Survey. J Rheumatol. 2019 Jun;46(6):564-571. 32. Rollefstad S, Ikdahl E, Wibetoe G, et al. An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis-results from 19 countries. Eur Heart J Cardiovasc Pharmacother. 2022:6:539-548. 33. Semb AG, Rollefstad S, Ikdahl E, et al. Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. RMD Open. 2021;2:e001724. doi: 10.1136/rmdopen-2021-001724. 34. Agca R, Hopman LHGA, Laan KJC, et al. Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study. J Rheumatol. 2020;3:316-324. 35. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases 2017;76:17-28. 36. Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022 Jun;81(6):768-779. 37. Omair MA, Alkhelb SA, Ezzat SE, et al. Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors. Open Access Rheumatol. 2022 Oct 17;14:231-242. 38. Thomas K, Vassilopoulos D. Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies. Mediterr J Rheumatol. 2020 Jun 11;31(Suppl 1):129-136. 39. Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;1:e000935. doi: 10.1136/ rmdopen-2019-000935. 40. Accortt NA, Lesperance T, Liu M, et al. Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018 May;70(5):679-684. doi: 10.1002/acr.23426. Epub 2018 Mar 11. 41. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1074. 42. Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1755. 43. Beydon M, Pinto S, De Rycke Y, et al. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study. Lancet Reg Health Eur. 2023 Oct 30;35:100768. 44. Lange E, Blizzard L, Venn A,et al. Disease-modifying anti-rheumatic drugs and non- -melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study. Rheumatology (Oxford). 2016 Sep;55(9):1594-600. 45. Wang JL, Yin WJ, Zhou LY, et al. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis. Clin Rheumatol. 2020 Mar;39(3):769-778. Další literatura u autorky a na www.casopisvnitrnilekarstvi.cz
RkJQdWJsaXNoZXIy NDA4Mjc=